In various earlier studies, large-scale prostate cancer TMAs that included >3,000 patients were used to demonstrate the prognostic role of p53, HER2, EGFR, Ki67LI, 8p deletion and PSMA (23,24,35,37–39). This evidence concerns the gene ERBB2 and prostate cancer.